Regular treatment
PreclinicalSmall molecule
Innovent Biologics (Suzhou) Co. Ltd.Regular treatment is one of 11 small molecule programs targeting Cerebral Small Vessel Disease. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Cerebral Small Vessel Disease
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Pletal
OtsukaApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Trental
VValidus Pharmaceuticals
Approved
Viagra
VViatris Specialty LLC
Approved
Cialis
Eli LillyPhase 2
Tongxinluo
FFudan University
Phase 3
Bayer Aspirin
BayerPreclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
XBD173
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Psoriasis1 trial
Cerebral Small Vessel Disease1 trial
Remote Ischemic Conditioning on Cerebral Small Vessel Disease
Unknown status·—·N/A·NCT04816500·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Regular treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details